Jessing Thomas Damgaard, Fenger-Eriksen Christian
Ugeskr Laeger. 2016 Apr 11;178(15):V09150773.
Tranexamic acid inhibits the degradation of a newly formed fibrin clot. The drug reduces blood loss and transfusion requirements in a wide range of different clinical scenarios and patient settings. So far, tranexamic acid is not part of standard treatment among patients with gastrointestinal bleeding. This article evaluates the available literature on this topic. Tranexamic acid seems appropriate as adjuvant treatment during upper gastrointestinal bleeding. However, these patients are often old and have several co-morbidities. Therefore, thromboembolic risk and tranexamic acid dosage should be carefully evaluated.
氨甲环酸可抑制新形成的纤维蛋白凝块的降解。在广泛的不同临床场景和患者情况下，该药物可减少失血和输血需求。到目前为止，氨甲环酸并非胃肠道出血患者标准治疗的一部分。本文评估了关于这一主题的现有文献。氨甲环酸似乎适合作为上消化道出血期间的辅助治疗。然而，这些患者往往年事已高且有多种合并症。因此，应仔细评估血栓栓塞风险和氨甲环酸的剂量。
